
Israeli firm Teva has shared disappointing results for its vesicular monoamine transporter 2 (VMAT2) Austedo (deutetrabenazine) after it failed to …

Danish firm Lundbeck has agreed to acquire San Diego-based biotech Abide Therapeutics as part of a deal worth $400 million. …

Neurocrine’s Tourette’s therapy Ingrezza (valbenazine) has been hit with yet another setback, flopping in a Phase 2 trial of paediatric …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

